Hematology

Mayo Clinic

Questions discussed in this category

How do you approach the decision to pursue early versus delayed autologous stem cell transplantation in newly diagnosed multiple myeloma?

1 Answer available

What is your treatment of choice for triple class refractory multiple myeloma?

CAR-T (any specific preference of product?) vs bispecific antibodies vs any other specific agents not previously utilized?

2 Answers available

What is your preferred maintenance strategy for high risk multiple myeloma?

2 Answers available

Papers discussed in this category

The New England journal of medicine, 2012-05-10

Lenalidomide after stem-cell transplantation for multiple myeloma.

Nature communications, 2019-04-23

Multiple myeloma immunoglobulin lambda translocations portend poor prognosis.

Blood, 2012 Aug 13

Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial.

J Clin Oncol, 2020 Apr 16

Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma.

Blood,

Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-10-10

Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis.

The New England journal of medicine, 2017-04-06

Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.

The Lancet. Oncology, 2019-01

Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial.

Blood,

Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma.

Related Topics in Hematology